A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
A federal judge has issued a temporary pause across all states on the new NIH order that caps “indirect costs” for research grants—a move designed to slash costs by $4 billion per year. | A federal ...
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...
During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...
BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...
The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...
The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback